Pfizer’s Tanezumab REMS Faces US FDA Doubts Heading Into Panel Review

 
• By Sue Sutter
  
Knee replacement X-ray
Osteoarthritis progression leading to total joint replacement is among the safety issues flagged in FDA's review of tanezumab. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers